High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates.
5 affiliations
- 1Department of General, Visceral, Thoracic and Transplant Surgery, University Hospital Cologne, Kerpenertsr. 62, 50937, Cologne, Germany. [email protected].
- 2Department of Surgery, Center for Life Sciences, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. [email protected].
- 3Department of Urology, Uro-Oncology, Robot-Assisted, and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
- 4Institute of Pathology, University Hospital Cologne, Cologne, Germany.
- 5Department of General, Visceral, Thoracic and Transplant Surgery, University Hospital Cologne, Kerpenertsr. 62, 50937, Cologne, Germany.
Abstract
Purpose
Trophoblast cell surface antigen 2 (TROP2) is a glycoprotein expressed on epithelial tumor cells and therefore an established target for antibody-drug conjugates (ADCs). Epstein-Barr virus (EBV)-positive gastric cancer is a molecularly distinct subtype characterized by unique immunological features, including frequent responsiveness to immune checkpoint inhibitors (ICIs). Nevertheless, a subset of these patients fails to benefit from ICI therapy, leaving an unmet need for non-immunotherapeutic treatment options. Tumors lacking TROP2, fail to respond to TROP2-directed ADCs. We therefore assessed the prevalence of TROP2 expression in gastric cancer including the EBV-positive subtype, which has not been characterized to date.Methods
TROP2 expression was evaluated by immunohistochemistry in 525 patients with gastric cancer classified according to TCGA molecular subtypes, representing the largest Caucasian cohort assessed for TROP2 to date.Results
TROP2 expression differed significantly across molecular subtypes (p < 0.01), with EBV-positive tumors showing the highest median expression (H-score 150). Complete absence of TROP2, the expression pattern associated with treatment failure, was observed in only 3.7% of EBV-positive tumors, compared with 18.8% of chromosomal instability, 25.4% of genomically stable, and 36.2% of microsatellite instability tumors.Conclusion
Nearly all EBV-positive gastric cancers therefore express TROP2 at levels compatible with ADC targeting. These findings identify TROP2 as a target in EBV-positive gastric cancer and provide a rationale for clinical investigation of TROP2-directed ADCs in this molecularly defined population, particularly as a non-immunotherapeutic option for patients who fail ICI therapy.
Related
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
- Mechanism-Matched Pharmacology of Resistance in EGFR-Mutant NSCLC: Genomic Bypass, Lineage Plasticity, Antibody-Drug Conjugates, and Candidate Biophysical Targets
- Designer ⁶⁴Cu Porphyrin-Trastuzumab Conjugates for Imaging of HER2-Positive Breast Cancer.
- Integrated Transcriptomic Analysis Identifies ENO3 as a Candidate Lactate Metabolism‐Associated Biomarker in Colorectal Cancer Metastasis
- Exploratory Integration of Metabolomics and Machine Learning Identifies Candidate Signatures of Spontaneous Preterm Birth
BibTeX
@article{wagner2026high,
title = {{High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates.}},
author = {Tristan Wagner and Richard Weiten and Su Ir Lyu and Aylin Pamuk and Axel Heidenreich and Christiane J Bruns and Alexander Quaas and Hakan Alakus and Nikolai Schleussner},
journal = {Langenbeck's archives of surgery},
year = {2026},
month = oct,
doi = {10.1007/s00423-026-04340-8},
url = {https://europepmc.org/article/MED/42925415},
note = {CC BY},
}
RIS
TY - JOUR
TI - High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates.
AU - Tristan Wagner
AU - Richard Weiten
AU - Su Ir Lyu
AU - Aylin Pamuk
AU - Axel Heidenreich
AU - Christiane J Bruns
AU - Alexander Quaas
AU - Hakan Alakus
AU - Nikolai Schleussner
PY - 2026
DA - 2026/10/24
JO - Langenbeck's archives of surgery
DO - 10.1007/s00423-026-04340-8
UR - https://europepmc.org/article/MED/42925415
AB - Purpose Trophoblast cell surface antigen 2 (TROP2) is a glycoprotein expressed on epithelial tumor cells and therefore an established target for antibody-drug conjugates (ADCs). Epstein-Barr virus (EBV)-positive gastric cancer is a molecularly distinct subtype characterized by unique immunological features, including frequent responsiveness to immune checkpoint inhibitors (ICIs). Nevertheless, a subset of these patients fails to benefit from ICI therapy, leaving an unmet need for non-immunotherapeutic treatment options. Tumors lacking TROP2, fail to respond to TROP2-directed ADCs. We therefore assessed the prevalence of TROP2 expression in gastric cancer including the EBV-positive subtype, which has not been characterized to date.Methods TROP2 expression was evaluated by immunohistochemistry in 525 patients with gastric cancer classified according to TCGA molecular subtypes, representing the largest Caucasian cohort assessed for TROP2 to date.Results TROP2 expression differed significantly across molecular subtypes (p < 0.01), with EBV-positive tumors showing the highest median expression (H-score 150). Complete absence of TROP2, the expression pattern associated with treatment failure, was observed in only 3.7% of EBV-positive tumors, compared with 18.8% of chromosomal instability, 25.4% of genomically stable, and 36.2% of microsatellite instability tumors.Conclusion Nearly all EBV-positive gastric cancers therefore express TROP2 at levels compatible with ADC targeting. These findings identify TROP2 as a target in EBV-positive gastric cancer and provide a rationale for clinical investigation of TROP2-directed ADCs in this molecularly defined population, particularly as a non-immunotherapeutic option for patients who fail ICI therapy.
SN - 1435-2443
SN - 1435-2451
ER -